1
|
Manna S, Werren JP, Ortika BD, Bellich B, Pell CL, Nikolaou E, Gjuroski I, Lo S, Hinds J, Tundev O, Dunne EM, Gessner BD, Bentley SD, Russell FM, Mulholland EK, Mungun T, von Mollendorf C, Licciardi PV, Cescutti P, Ravenscroft N, Hilty M, Satzke C. Streptococcus pneumoniae serotype 33G: genetic, serological, and structural analysis of a new capsule type. Microbiol Spectr 2024; 12:e0357923. [PMID: 38059623 PMCID: PMC10782959 DOI: 10.1128/spectrum.03579-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2023] [Accepted: 11/09/2023] [Indexed: 12/08/2023] Open
Abstract
IMPORTANCE Streptococcus pneumoniae (the pneumococcus) is a bacterial pathogen with the greatest burden of disease in Asia and Africa. The pneumococcal capsular polysaccharide has biological relevance as a major virulence factor as well as public health importance as it is the target for currently licensed vaccines. These vaccines have limited valency, covering up to 23 of the >100 known capsular types (serotypes) with higher valency vaccines in development. Here, we have characterized a new pneumococcal serotype, which we have named 33G. We detected serotype 33G in nasopharyngeal swabs (n = 20) from children and adults hospitalized with pneumonia, as well as healthy children in Mongolia. We show that the genetic, serological, and biochemical properties of 33G differ from existing serotypes, satisfying the criteria to be designated as a new serotype. Future studies should focus on the geographical distribution of 33G and any changes in prevalence following vaccine introduction.
Collapse
Affiliation(s)
- Sam Manna
- Infection, Immunity, and Global Health, Murdoch Children’s Research Institute, Melbourne, Australia
- Department of Pediatrics, The University of Melbourne, Melbourne, Australia
- Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
| | - Joel P. Werren
- Institute for Infectious Diseases, University of Bern, Bern, Switzerland
| | - Belinda D. Ortika
- Infection, Immunity, and Global Health, Murdoch Children’s Research Institute, Melbourne, Australia
| | - Barbara Bellich
- Department of Life Sciences, University of Trieste, Trieste, Italy
| | - Casey L. Pell
- Infection, Immunity, and Global Health, Murdoch Children’s Research Institute, Melbourne, Australia
| | - Elissavet Nikolaou
- Infection, Immunity, and Global Health, Murdoch Children’s Research Institute, Melbourne, Australia
- Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
| | - Ilche Gjuroski
- Department of Chemistry and Biochemistry, University of Bern, Bern, Switzerland
| | - Stephanie Lo
- Parasites and Microbes, Wellcome Sanger Institute, Hinxton, United Kingdom
| | - Jason Hinds
- Institute for Infection and Immunity, St. George’s, University of London, London, United Kingdom
- BUGS Bioscience, London Bioscience Innovation Center, London, United Kingdom
| | - Odgerel Tundev
- National Center for Communicable Diseases, Ministry of Health, Ulaanbaatar, Mongolia
| | | | | | - Stephen D. Bentley
- Parasites and Microbes, Wellcome Sanger Institute, Hinxton, United Kingdom
| | - Fiona M. Russell
- Infection, Immunity, and Global Health, Murdoch Children’s Research Institute, Melbourne, Australia
- Department of Pediatrics, The University of Melbourne, Melbourne, Australia
| | - E. Kim Mulholland
- Infection, Immunity, and Global Health, Murdoch Children’s Research Institute, Melbourne, Australia
- Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Tuya Mungun
- National Center for Communicable Diseases, Ministry of Health, Ulaanbaatar, Mongolia
| | - Claire von Mollendorf
- Infection, Immunity, and Global Health, Murdoch Children’s Research Institute, Melbourne, Australia
- Department of Pediatrics, The University of Melbourne, Melbourne, Australia
| | - Paul V. Licciardi
- Infection, Immunity, and Global Health, Murdoch Children’s Research Institute, Melbourne, Australia
- Department of Pediatrics, The University of Melbourne, Melbourne, Australia
| | - Paola Cescutti
- Department of Life Sciences, University of Trieste, Trieste, Italy
| | - Neil Ravenscroft
- Department of Chemistry, University of Cape Town, Rondebosch, South Africa
| | - Markus Hilty
- Institute for Infectious Diseases, University of Bern, Bern, Switzerland
| | - Catherine Satzke
- Infection, Immunity, and Global Health, Murdoch Children’s Research Institute, Melbourne, Australia
- Department of Pediatrics, The University of Melbourne, Melbourne, Australia
- Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia
| |
Collapse
|
2
|
McGuinness D, Kaufhold RM, McHugh PM, Winters MA, Smith WJ, Giovarelli C, He J, Zhang Y, Musey L, Skinner JM. Immunogenicity of PCV24, an expanded pneumococcal conjugate vaccine, in adult monkeys and protection in mice. Vaccine 2021; 39:4231-4237. [PMID: 34074546 DOI: 10.1016/j.vaccine.2021.04.067] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2021] [Revised: 04/23/2021] [Accepted: 04/30/2021] [Indexed: 11/20/2022]
Abstract
Invasive pneumococcal disease (IPD) is responsible for serious illnesses such as bacteremia, sepsis, meningitis, and pneumonia in young children, older adults, and persons with immunocompromising conditions and often leads to death. Although the most recent pneumococcal conjugate vaccines (PCVs) have been designed to target serotypes identified as the primary causative agents of IPD, the epidemiological landscape continues to change stressing the need to develop new PCVs. We have developed an investigational 24-valent PCV (PCV24) including serotypes 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F all conjugated to CRM197 and evaluated this vaccine in adult monkeys. PCV24 was shown to be immunogenic and induced functional antibody for all vaccine serotypes. Of the serotypes common to PCV13 and V114 (PCV15), PCV24 had a similar immunogenic response with the exceptions of 23F which had higher IgG GMCs for PCV13 and V114, and 7F which had higher GMCs for PCV13. Functional antibody responses were similar for the serotypes in common between PCV24, PCV13 and V114 vaccines, with the exception of serotype 7F which was greater for PCV13. Overall, this study shows that PCV24 provided similar immunogenicity as the lower valent vaccines in adult monkeys with no apparent serotype interference. In addition, PCV24 also provided protection against pneumococcal infection in a mouse challenge model.
Collapse
Affiliation(s)
- Debra McGuinness
- Departments of Infectious Diseases/Vaccines, Merck & Co., Inc., West Point, PA, USA.
| | - Robin M Kaufhold
- Departments of Infectious Diseases/Vaccines, Merck & Co., Inc., West Point, PA, USA
| | - Patrick M McHugh
- Departments of Vaccine Process Research & Development, Merck & Co., Inc., West Point, PA, USA
| | - Michael A Winters
- Departments of Vaccine Process Research & Development, Merck & Co., Inc., West Point, PA, USA
| | - William J Smith
- Departments of Vaccine Process Research & Development, Merck & Co., Inc., West Point, PA, USA
| | - Cecilia Giovarelli
- Departments of Vaccine Process Research & Development, Merck & Co., Inc., West Point, PA, USA
| | - Jian He
- Departments of Vaccine Process Research & Development, Merck & Co., Inc., West Point, PA, USA
| | - Yuhua Zhang
- Departments of Non-clinical Statistics, Merck & Co., Inc., West Point, PA, USA
| | - Luwy Musey
- Departments of Clinical Research, Merck & Co., Inc., West Point, PA, USA
| | - Julie M Skinner
- Departments of Infectious Diseases/Vaccines, Merck & Co., Inc., West Point, PA, USA
| |
Collapse
|
3
|
Schaballie H, Wuyts G, Dillaerts D, Frans G, Moens L, Proesmans M, Vermeulen F, De Boeck K, Meyts I, Bossuyt X. Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses. Clin Exp Immunol 2016; 185:180-9. [PMID: 26939935 DOI: 10.1111/cei.12784] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/29/2016] [Indexed: 11/30/2022] Open
Abstract
During the past 10 years, pneumococcal conjugate vaccine (PCV) has become part of the standard childhood vaccination programme. This may impact upon the diagnosis of polysaccharide antibody deficiency by measurement of anti-polysaccharide immunoglobulin (Ig)G after immunization with unconjugated pneumococcal polysaccharide vaccine (PPV). Indeed, contrary to PPV, PCV induces a T-dependent, more pronounced memory response. The antibody response to PPV was studied retrospectively in patients referred for suspected humoral immunodeficiency. The study population was divided into four subgroups based on age (2-5 years versus ≥ 10 years) and time tested (1998-2005 versus 2010-12). Only 2-5-year-old children tested in 2010-12 had been vaccinated with PCV prior to PPV. The PCV primed group showed higher antibody responses for PCV-PPV shared serotypes 4 and 18C than the unprimed groups. To a lesser extent, this was also found for non-PCV serotype 9N, but not for non-PCV serotypes 19A and 8. Furthermore, PCV-priming elicited a higher IgG2 response. In conclusion, previous PCV vaccination affects antibody response to PPV for shared serotypes, but can also influence antibody response to some non-PCV serotypes (9N). With increasing number of serotypes included in PCV, the diagnostic assessment for polysaccharide antibody deficiency requires careful selection of serotypes that are not influenced by prior PCV (e.g. serotype 8). Further research is needed to identify more serotypes that are not influenced.
Collapse
Affiliation(s)
- H Schaballie
- Department of Pediatrics, University Hospitals Leuven.,Department of Microbiology and Immunology, KU Leuven - University of Leuven
| | - G Wuyts
- Department of Microbiology and Immunology, KU Leuven - University of Leuven
| | - D Dillaerts
- Department of Microbiology and Immunology, KU Leuven - University of Leuven
| | - G Frans
- Department of Microbiology and Immunology, KU Leuven - University of Leuven.,Department of Laboratory Medicine, University Hospitals Leuven, Belgium
| | - L Moens
- Department of Microbiology and Immunology, KU Leuven - University of Leuven
| | - M Proesmans
- Department of Pediatrics, University Hospitals Leuven
| | - F Vermeulen
- Department of Pediatrics, University Hospitals Leuven
| | - K De Boeck
- Department of Pediatrics, University Hospitals Leuven
| | - I Meyts
- Department of Pediatrics, University Hospitals Leuven.,Department of Microbiology and Immunology, KU Leuven - University of Leuven
| | - X Bossuyt
- Department of Microbiology and Immunology, KU Leuven - University of Leuven.,Department of Laboratory Medicine, University Hospitals Leuven, Belgium
| |
Collapse
|
4
|
Licciardi PV, Balloch A, Russell FM, Burton RL, Lin J, Nahm MH, Mulholland EK, Tang MLK. Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses. J Allergy Clin Immunol 2012; 129:794-800.e2. [PMID: 22305678 DOI: 10.1016/j.jaci.2011.11.043] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2011] [Revised: 11/10/2011] [Accepted: 11/15/2011] [Indexed: 10/14/2022]
Abstract
BACKGROUND Infections with Streptococcus pneumoniae (pneumococcus) are a cause of significant child mortality. Pneumococcal glycoconjugate vaccines are expensive and provide limited serotype coverage. The 23-valent pneumococcal polysaccharide vaccine (Pneumovax) might provide wider serotype coverage but is reported to be weakly immunogenic in children less than 2 years of age. We have previously reported that Pneumovax administered to healthy 12-month-old Fijian infants elicits significant serotype-specific IgG responses. However, the functional capacity of these responses in 12-month-old infants is not known. OBJECTIVE We sought to assess the functional, serotype-specific immune response of 12-month-old infants after immunization with Pneumovax. METHODS Functional responses of 12-month-old infants were assessed by using the opsonophagocytic and antibody avidity assay against 8 serotypes and 23 serotypes, respectively. RESULTS Seventy-one percent of infants produced strong opsonophagocytic activity against 4 of 8 serotypes, and 30% produced high-avidity serotype-specific IgG antibodies to 10 of 23 serotypes at 2 weeks after Pneumovax. Responses were protective for most serotypes that cause disease in Western countries, whereas responses to most of the epidemiologically relevant serotypes for developing countries were low. CONCLUSION This is the first comprehensive study evaluating the functional antibody response to Pneumovax in 12-month-old infants. Pneumovax induced functional antibody responses to several serotypes causing disease in Western countries but induced poorer responses to serotypes that are responsible for the majority of disease in developing countries. Pneumovax might be of benefit in some populations, but further studies are required before this can be recommended in developing countries.
Collapse
Affiliation(s)
- Paul V Licciardi
- Pneumococcal Laboratory, Murdoch Childrens Research Institute, Melbourne, Australia
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Russell FM, Balloch A, Licciardi PV, Carapetis JR, Tikoduadua L, Waqatakirewa L, Cheung YB, Mulholland EK, Tang MLK. Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months. Vaccine 2011; 29:4499-506. [PMID: 21539882 PMCID: PMC3114163 DOI: 10.1016/j.vaccine.2011.04.038] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2010] [Revised: 04/01/2011] [Accepted: 04/12/2011] [Indexed: 11/29/2022]
Abstract
AIM To evaluate whether the avidity of serotype-specific IgG to pneumococcal serotypes is enhanced by an increased number of doses of the 7-valent pneumococcal conjugate vaccine (PCV) in infancy or by a 12 month 23-valent pneumococcal polysaccharide vaccine (23vPPS) booster, and/or subsequent re-exposure to a small dose of pneumococcal polysaccharide antigens (mPPS) at 17 months. METHODS Fijian infants aged 6 weeks were recruited, stratified by ethnicity and randomized to 8 groups to receive 0, 1, 2, or 3 doses of PCV, with or without 23vPPS at 12 months. All children received mPPS at 17 months of age. Avidity of serotype-specific IgG for PCV serotypes in the first 12 months and for all 23vPPS serotypes thereafter was assessed by EIA after sodium thiocyanate elution. RESULTS At one month post primary series, the 2 and 3 PCV dose groups demonstrated similar avidity, with the single dose group tending to have lower avidity. However, by age 9 months, the single dose group had similar avidity to the 2 and 3 PCV groups for most serotypes. The 23vPPS booster enhanced affinity maturation for most serotypes and this was most marked in those groups that received a single PCV dose. There was little further increase following the mPPS. CONCLUSIONS By 9 months of age, similar avidity can be induced following one, 2 or 3 doses of PCV. A 23vPPS booster at 12 months enhanced affinity maturation with an increase in antibody avidity for most serotypes. Subsequent re-challenge with mPPS at 17 months did not further enhance the avidity of serotype-specific response in the 12 month 23vPPS groups.
Collapse
Affiliation(s)
- F M Russell
- Centre for International Child Health, Department of Paediatrics, University of Melbourne, Royal Children's Hospital, Melbourne, Australia.
| | | | | | | | | | | | | | | | | |
Collapse
|